Logo image of RNTX

REIN THERAPEUTICS INC (RNTX) Stock Price, Quote, News and Overview

NASDAQ:RNTX - Nasdaq - US00887A2042 - Common Stock - Currency: USD

1.88  -0.09 (-4.57%)

RNTX Quote, Performance and Key Statistics

REIN THERAPEUTICS INC

NASDAQ:RNTX (6/13/2025, 8:00:02 PM)

1.88

-0.09 (-4.57%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap41.64M
Shares22.15M
Float22.13M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-12 2025-08-12
IPO06-29 2017-06-29


RNTX short term performance overview.The bars show the price performance of RNTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20

RNTX long term performance overview.The bars show the price performance of RNTX in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of RNTX is 1.88 USD. In the past month the price decreased by -20.34%.

REIN THERAPEUTICS INC / RNTX Daily stock chart

RNTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.61 337.52B
AMGN AMGEN INC 14.22 158.74B
GILD GILEAD SCIENCES INC 14.21 136.81B
VRTX VERTEX PHARMACEUTICALS INC N/A 116.96B
REGN REGENERON PHARMACEUTICALS 11.94 57.14B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 40.16B
ARGX ARGENX SE - ADR 100.5 35.29B
ONC BEONE MEDICINES LTD-ADR 6.9 29.17B
BNTX BIONTECH SE-ADR N/A 25.62B
NTRA NATERA INC N/A 22.58B
BIIB BIOGEN INC 8.26 19.14B
INSM INSMED INC N/A 17.98B

About RNTX

Company Profile

RNTX logo image Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. The company is headquartered in Austin, Texas and currently employs 11 full-time employees. The company went IPO on 2017-06-29. The firm's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).

Company Info

REIN THERAPEUTICS INC

12407 N. Mopac Expy., Suite 250 #390

Austin TEXAS US

Employees: 11

RNTX Company Website

RNTX Investor Relations

Phone: 17378021989

REIN THERAPEUTICS INC / RNTX FAQ

What is the stock price of REIN THERAPEUTICS INC today?

The current stock price of RNTX is 1.88 USD. The price decreased by -4.57% in the last trading session.


What is the ticker symbol for REIN THERAPEUTICS INC stock?

The exchange symbol of REIN THERAPEUTICS INC is RNTX and it is listed on the Nasdaq exchange.


On which exchange is RNTX stock listed?

RNTX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for REIN THERAPEUTICS INC stock?

8 analysts have analysed RNTX and the average price target is 10.2 USD. This implies a price increase of 442.55% is expected in the next year compared to the current price of 1.88. Check the REIN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is REIN THERAPEUTICS INC worth?

REIN THERAPEUTICS INC (RNTX) has a market capitalization of 41.64M USD. This makes RNTX a Nano Cap stock.


How many employees does REIN THERAPEUTICS INC have?

REIN THERAPEUTICS INC (RNTX) currently has 11 employees.


What are the support and resistance levels for REIN THERAPEUTICS INC (RNTX) stock?

REIN THERAPEUTICS INC (RNTX) has a support level at 1.87 and a resistance level at 1.92. Check the full technical report for a detailed analysis of RNTX support and resistance levels.


Should I buy REIN THERAPEUTICS INC (RNTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does REIN THERAPEUTICS INC (RNTX) stock pay dividends?

RNTX does not pay a dividend.


When does REIN THERAPEUTICS INC (RNTX) report earnings?

REIN THERAPEUTICS INC (RNTX) will report earnings on 2025-08-12.


What is the Price/Earnings (PE) ratio of REIN THERAPEUTICS INC (RNTX)?

REIN THERAPEUTICS INC (RNTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.17).


What is the Short Interest ratio of REIN THERAPEUTICS INC (RNTX) stock?

The outstanding short interest for REIN THERAPEUTICS INC (RNTX) is 0.51% of its float. Check the ownership tab for more information on the RNTX short interest.


RNTX Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to RNTX.


Chartmill TA Rating
Chartmill Setup Rating

RNTX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to RNTX. RNTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RNTX Financial Highlights

Over the last trailing twelve months RNTX reported a non-GAAP Earnings per Share(EPS) of -3.17.


Industry RankSector Rank
PM (TTM) N/A
ROA -28.06%
ROE -30.71%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%70.93%
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A

RNTX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to RNTX. The Buy consensus is the average rating of analysts ratings from 8 analysts.


Ownership
Inst Owners24.45%
Ins Owners0.09%
Short Float %0.51%
Short Ratio2.96
Analysts
Analysts85
Price Target10.2 (442.55%)
EPS Next Y78.68%
Revenue Next YearN/A